Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription 26.05.2025 2 BMC Cancer 1 Clin Cancer Res 1 Eur J Obstet Gynecol Reprod Biol 3 Gynecol Oncol 1 Int J Gynaecol Obstet 1 J Clin Oncol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. GUAN X, Liao S, Zhang F, Zhu Q, et al
   Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing.
   BMC Cancer. 2025;25:924.
   PubMed         Abstract available
   
   
2. LENG Y, Zhou J, Liu W, Luo F, et al
   A CT-based radiomics model for predicting progression-free survival in patients with epithelial ovarian cancer.
   BMC Cancer. 2025;25:899.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

3. COLLET L, Ardin M, Venet D, Berthet J, et al
   Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
   Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2712.
   PubMed         Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

4. EINIG S, Puls T, Reina H, Schoetzau A, et al
   External validation of the IOTA two-step strategy in the preoperative characterization of ovarian masses.
   Eur J Obstet Gynecol Reprod Biol. 2025;310:113981.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
   Hysterectomy or not for borderline ovarian tumor in menopause?
   Gynecol Oncol. 2025;196:152-159.
   PubMed         Abstract available
   
   
6. METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
   Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
   Gynecol Oncol. 2025;196:129-136.
   PubMed         Abstract available
   
   
7. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
   ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
   Gynecol Oncol. 2025;196:113-120.
   PubMed         Abstract available
   
   

   
   Int J Gynaecol Obstet

8. OZCIVIT ERKAN IB, Kuru O, Turker Saricoban C, Wardak M, et al
   Unusual synchronous and metachronous association of hematologic neoplasms with gynecologic neoplasms: A case series and literature review.
   Int J Gynaecol Obstet. 2024 Dec 6. doi: 10.1002/ijgo.16075.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. SHAH M, Chen TY, Ison G, Fiero MH, et al
   Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
   J Clin Oncol. 2025 May 19:JCO2402834. doi: 10.1200/JCO-24-02834.
   PubMed         Abstract available
   
   

   
   PLoS One

10. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed         Abstract available
    
    
11. KIM TH, Memarzadeh S, Vahdatshariatpanahi S, Ostrzega N, et al
    Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers.
    PLoS One. 2025;20:e0322744.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.